Skip to main content

Advertisement

SpringerLink
Log in

Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development

  • Perspective
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Mechanistic PKPD models are now advocated not only by academic and industrial researchers, but also by regulators. A recent development in this area is based on the growing realisation that innovation could be dramatically catalysed by creating synergy at the interface between Systems Biology and PKPD, two disciplines which until now have largely existed in ‘parallel universes’ with a limited track record of impactful collaboration. This has led to the emergence of systems pharmacology. Broadly speaking, this is the quantitative analysis of the dynamic interactions between drug(s) and a biological system to understand the behaviour of the system as a whole, as opposed to the behaviour of its individual constituents; thus, it has become the interface between PKPD and systems biology. It applies the concepts of Systems Engineering, Systems Biology, and PKPD to the study of complex biological systems through iteration between computational and/or mathematical modelling and experimentation. Application of systems pharmacology can now impact across all stages of drug research and development, ranging from very early discovery programs to large-scale Phase 3/4 patient studies, and has the potential to become an integral component of a new ‘enhanced quantitative drug discovery and development’ (EQD3) R&D paradigm.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

REFERENCES

  1. Zhang L, Pfister M, Meibohm B. Concepts and challenges in quantitative pharmacology and model-based drug development. AAPS J. 2008;10:552–9.

    Article  PubMed  CAS  Google Scholar 

  2. Gobburu JVS, Lesko LJ. Quantitative disease, drug and trial models. Ann Rev Pharmacol Toxicol. 2009;49:291–301.

    Article  CAS  Google Scholar 

  3. Williams PJ, Ette EI. Pharmacometrics—impacting drug development and pharmacotherapy. In: Ette EI, Williams PJ, editors. Pharmacometrics—The science of quantitative pharmacology. Hoboken: Wiley; 2007. p. 1–21.

    Google Scholar 

  4. Danhof M, Van der Graaf PH, Jonker DM, Visser SAG, Zuideveld KP. Mechanism-based pharmacokinetic–pharmacodynamic modeling for the prediction of in vivo drug concentration–effect relationships—application in drug candidate selection and lead optimization. In: Testa B, Van de Waterbeemd H (eds) Comprehensive Medicinal Chemistry II (Part 5). Elsevier; 2007. p. 885–908.

  5. Ploeger BA, Van der Graaf PH, Danhof M. Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling. Drug Metab Pharmacokinet. 2009;24:3–15.

    Article  PubMed  CAS  Google Scholar 

  6. Mager DE, Woo S, Jusko WJ. Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet. 2009;24:16–24.

    Article  PubMed  CAS  Google Scholar 

  7. Van der Graaf PH, Gabrielsson J. Pharmacokinetic-pharmacodynamic reasoning in drug discovery and early development. Future Med Chem. 2009;1:1371–4.

    Article  Google Scholar 

  8. Gabrielsson J, Green AR, Van Der Graaf PH. Optimising in vivo pharmacology studies–Practical PKPD considerations. J Pharmacol Toxicol Methods. 2010;61:146–56.

    Article  PubMed  CAS  Google Scholar 

  9. Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov. 2004;3:711–5.

    Article  PubMed  CAS  Google Scholar 

  10. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009;8:959–68.

    Article  PubMed  CAS  Google Scholar 

  11. Gabrielsson J, Fjellstrom O, Ulander J, Rowley M, Van Der Graaf PH. Pharmacodynamic-pharmacokinetic integration as a guide to medicinal chemistry. Curr Top Med Chem. 2011;11:404–18.

    Article  PubMed  CAS  Google Scholar 

  12. Agoram BM, Martin SW, Van der Graaf PH. The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics. Drug Discov Today. 2007;12:1018–24.

    Article  PubMed  CAS  Google Scholar 

  13. Kenakin TP. Cellular assays as portals to seven-transmembrane receptor-based drug discovery. Nat Rev Drug Discov. 2009;8:617–26.

    Article  PubMed  CAS  Google Scholar 

  14. Langdon G, Davis JD, McFadyen LM, Dewhurst M, Brunton NS, Rawal JK, et al. Translational pharmacokinetic-pharmacodynamic modelling; application to cardiovascular safety data for PF-00821385, a novel HIV agent. Br J Clin Pharmacol. 2010;69:336–45.

    Article  PubMed  CAS  Google Scholar 

  15. Berg JM, Rogers ME, Lyster PM. Systems Biology and Pharmacology. Clin Pharmacol Ther. 2010;88:17–9.

    Article  PubMed  CAS  Google Scholar 

  16. Quantitative and Systems Pharmacology Workshop II: http://meetings.nigms.nih.gov/index.cfm?event=home&ID=8316

  17. Jensen ON. Modification-specific proteomics: characterization of post-translational modifications by mass spectrometry. Curr Opin Chem Biol. 2004;8:33–41.

    Article  PubMed  Google Scholar 

  18. Van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, O’Collins V, et al. Can animal models of disease reliably inform human studies? PLoS Med. 2010;7:1–8.

    Google Scholar 

  19. Kohl P, Crampin EJ, Quinn TA, Noble D. Systems biology: an approach. Clin Pharmacol Ther. 2010;88:25–33.

    Article  PubMed  CAS  Google Scholar 

  20. Swat M, Kielbasa SM, Polak S, Olivier B, Bruggeman FJ, Quinton Tulloch M, et al. What it takes to understand and cure a living system: computational systems biology and systems biology-driven pharmacokinetics-pharmacodynamics platform. Interface Focus. 2011;1:16–23.

    Google Scholar 

  21. Cohen A. Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development-designing informative human pharmacological studies. Clin Pharmacokin. 2008;47:373–81.

    Article  CAS  Google Scholar 

  22. Systems biology: a vision for engineering and medicine. A report from the Academy of Medical Sciences and The Royal Academy of Engineering (2007). http://raeng.org.uk/policy/engagement/pdf/systems_biology_report.pdf.

  23. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G. Mechanism-based pharmacokinetic-pharmacodynamic modelling—a new classification of biomarkers. Pharm Res. 2005;22:1432–7.

    Article  PubMed  CAS  Google Scholar 

  24. Aston PJ, Derks G, Raji A, Agoram BA, Van Der Graaf PH. Mathematical analysis of the pharmacokinetic-pharmacodynamic (PKPD) behaviour of monoclonal antibodies: predicting in vivo potency. J Theor Biol. 2011. doi:10.1016/j.jtbi.2011.04.030.

  25. Putnam WS, Li J, Haggstrom J, Ng C, Kadkhodayan-Fischer S, Cheu M, et al. Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody. AAPS J. 2008;10:425–30.

    Article  PubMed  CAS  Google Scholar 

  26. Van Der Graaf PH. Biomarkers and Biomeasures: key enablers for translational PK/PD in drug discovery and development. Keynote lecture at The Joint Pharmaceutical Analysis Group (JPAG) Biomarkers 2011 Workshop, London 2011, http://www.pjonline.com/meeting/biomarkers2011.

Download references

Author information

Authors and Affiliations

  1. Pfizer, Department of Pharmacometrics, Global Clinical Pharmacology, IPC 096, Sandwich, CT13 9NJ, UK

    Piet H. van der Graaf

  2. Pfizer Department of Pharmacokinetics, Dynamics & Metabolism (PDM), Sandwich, CT13 9NJ, UK

    Piet H. van der Graaf & Neil Benson

Authors
  1. Piet H. van der Graaf
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Neil Benson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Piet H. van der Graaf.

Rights and permissions

Reprints and permissions

About this article

Cite this article

van der Graaf, P.H., Benson, N. Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development. Pharm Res 28, 1460–1464 (2011). https://doi.org/10.1007/s11095-011-0467-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-011-0467-9

KEY WORDS

Search

Navigation